Detalhe da pesquisa
1.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33657295
2.
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Breast Cancer Res
; 21(1): 78, 2019 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31277699
3.
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
Eur Urol
; 77(4): 449-453, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31732098
4.
Diffuse cutaneous breast cancer metastases resembling subcutaneous nodules with no surface changes.
Cutis
; 101(3): 219-223, 2018 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-29718016
5.
Breast cancer prognostic biomarker using attractor metagenes and the FGD3-SUSD3 metagene.
Cancer Epidemiol Biomarkers Prev
; 23(12): 2850-6, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25249324
6.
Metformin and erlotinib synergize to inhibit basal breast cancer.
Oncotarget
; 5(21): 10503-17, 2014 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25361177
7.
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.
J Oncol Pract
; 8(5): e100-4, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23277771